Combating 2019-nCoV: Advanced Nanobiosensing platforms for POC global diagnostics and surveillance
- Funded by European Commission
- Total publications:8 publications
Grant number: 101003544
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$2,903,753.28Funder
European CommissionPrincipal Investigator
LECHUGA LauraResearch Location
SpainLead Research Institution
FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIAResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The recent outbreak in China caused by the emerging nCoV virus is challenging the level of global readiness from governments, public organizations and community to face and manage both its social and health consequences. Once the emergence is recognized and identified, it is crucial to initiate the necessary measures to prevent the spread. This involves therapeutics, vaccines, and devising efficient, fast, readily accessible diagnostics methods that specifically confirm the presence of the virus. Early detection can allow the rapid implementation of containment measures, which are the key to reduce the risk of amplification. The aim of CoNVat is to implement a Point-of-care label free biosensor for the direct, fast and specific identification of nCoV in decentralized settings to improve its early diagnosis and the clinical management of patients. The approach employs an already developed technology based on nanophotonic bimodal waveguide (BiMW) interferometers capable of providing real time, highly sensitive detections assays in short sample turnaround times. We propose two different strategies: (i) the development of a fast antigen-based diagnostic test for the specific detection of the intact virus in patient'Äôs samples such as respiratory specimens and non-respiratory fluids (serum, urine'Ķ) to be deployed to clinical settings for initial screening and (ii) development of a multiplexed molecular test, PCR-free, for the reliable identification of nCoV, being possible to differentiate the type and strain of coronavirus form other related or more common respiratory viruses. This latter strategy will provide a disruptive diagnostic tool not only from a clinical perspective to improve patient'Äôs outcome but also for surveillance, to study and understand possible transmission routes of this virus by analysing samples from animal reservoirs. Final prototype validation will demonstrate the potential of this approach for the management of future infectious outbreaks.
Publicationslinked via Europe PMC
Last Updated:43 minutes ago
View all publications at Europe PMC